FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   WEG KENNETH E 2. Date of Event Requiring Statement (Month/Day/Year) 03/11/2010 3. Issuer Name and Ticker or Trading Symbol AVEO PHARMACEUTICALS INC [AVEO] (Last) (First) (Middle) C/O AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) CAMBRIDGE, MA 02139 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 125,000 I By The Weg Family Limited Partnership (1) Common Stock 10,000 I By Clearview Venture Partners, LLC (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	  (3)	06/16/2019	Common Stock	10,000	$ 8.72	D	Â
Series D Convertible Preferred Stock	04/02/2009	  (4)	Common Stock	41,492	$ (4)	D	Â
Series A Convertible Preferred Stock	05/10/2002	  (5)	Common Stock	200,000	$ (5)	I	By The Weg Family Limited Partnership. (1)
Series B Convertible Preferred Stock	01/11/2007	  (6)	Common Stock	230,769	$ (6)	I	By The Weg Family Limited Partnership. (1)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
WEG KENNETH E C/O AVEO PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE, MA 02139	  X	Â	Â	Â

Signatures

/s/ Joseph D. Vittiglio, attorney-in-fact		03/11/2010
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Shares are held by The Weg Family Limited Partnership. Mr. Weg is a member of The Weg Family Limited Partnership and may be deemed to have voting and investment power over shares held of record by it. Mr. Weg disclaims beneficial ownership over shares held of record by The Weg Family Limited Partnership except to the extent of his pecuniary interest therein.
(2)	Shares are held by Clearview Venture Partners, LLC. Mr. Weg is a founder and a member of the board of directors of Clearview Venture Partners, LLC and may be deemed to have voting and investment power over shares held of record by it. Mr. Weg disclaims beneficial ownership over shares held of record by Clearview Venture Partners, LLC except to the extent of his pecuniary interest therein.
(3)	This option first became exercisable on July 31, 2009 and vests over a one-year period in equal monthly installments.
(4)	The Series D Convertible Preferred Stock is convertible into Common Stock on a one-for-0.25 basis and has no expiration date.
(5)	The Series A Convertible Preferred Stock is convertible into Common Stock on a one-for-0.25 basis and has no expiration date.
(6)	The Series B Convertible Preferred Stock is convertible into Common Stock on a one-for-0.25 basis and has no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.